Every 8-K that Perceptive Capital Solutions Corp (PCSC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PCSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSC filings page.
Freenome, Inc. has received FDA approval for SimpleScreen™ CRC, a blood-based screening test for colorectal cancer in adults aged 45 and older at average risk. The test analyzes cell-free DNA using AI/ML technology and was validated in the PREEMPT CRC study of more than 48,000 participants at over 200 sites.
In a prespecified analysis, SimpleScreen CRC showed 81.1% sensitivity for colorectal cancer, 13.7% sensitivity for advanced precancerous lesions (30.7% with high-grade dysplasia), and 90.4% specificity for advanced colorectal neoplasia. With approval, the test meets Medicare coverage criteria and is expected to be named in American Cancer Society guidelines, supporting broader access.
Under an August 2025 commercial agreement, Abbott will exclusively commercialize SimpleScreen CRC in the U.S. and will pay Freenome a $100 million milestone tied to this FDA approval. The product is the first commercial milestone in Freenome’s Personalized Cancer Detection strategy and will be integrated into its broader SimpleScreen portfolio and multiomics-based pipeline.
Freenome, Inc., formerly Perceptive Capital Solutions Corp., completed its business combination and domestication on July 20, 2026, ceasing to be a shell company and becoming the public parent of Freenome Holdings, Inc. Its common stock now trades on the Nasdaq Capital Market under the symbol FRNM.
New Freenome received gross proceeds of approximately $310.3 million in connection with the transaction, including $70.3 million from PCSC’s trust account and $240.0 million from a PIPE in which investors purchased 24,000,000 shares at $10.00 per share. Holders of 1,392,723 Class A shares redeemed at about $10.82 per share for roughly $15.1 million. Pro forma securities outstanding include 68,065,429 shares issued to former Freenome stockholders, 6,478,269 to PCSC shareholders, 2,442,500 to the sponsor and initial shareholders, plus options on 8,272,601 shares and RSUs on 4,034,512 shares. Shares of New Freenome common stock issued and outstanding totaled 107,446,814 as of the Closing Date.
An Investor Rights Agreement and PIPE subscription agreements provide registration rights covering about 65,440,613 shares, representing approximately 60.9% of outstanding common stock, and key holders are subject to a six‑month lock‑up. New Freenome adopted a 2026 Equity Incentive Plan initially reserving 14,773,227 shares (with an automatic 5% annual increase feature) and a 2026 Employee Stock Purchase Plan initially reserving 2,462,204 shares with capped annual increases. A new Executive Severance Plan, updated charter and bylaws, a staggered seven‑member board, and auditor transition to EY were also put in place. Major holders include Roche at 17.4%, RA Capital at 14.3%, Perceptive Life Sciences Master Fund at 12.4%, Andreessen Horowitz at 5.2%, and directors and officers as a group at 4.7%.
Perceptive Capital Solutions Corp. held an extraordinary general meeting on July 15, 2026, where shareholders approved the Business Combination Proposal with Freenome and related items, including the Domestication Proposal, updated governing documents, Nasdaq listing proposal, an equity incentive plan and an employee stock purchase plan.
Holders of 5,645,461 Class A and 2,156,250 Class B shares, representing approximately 75.65% of voting power as of the June 12, 2026 record date, were present, constituting a quorum. One proposal, for example, received 6,819,879 votes for, 980,832 against and 1,000 abstaining. An adjournment proposal was not needed because the required items had sufficient support.
Perceptive Capital Solutions Corp. is postponing its extraordinary general meeting to vote on the proposed business combination with Freenome. The meeting, originally set for July 9, 2026, will now take place on July 15, 2026 at 10:00 a.m. Eastern Time in New York and via virtual webcast.
The delay is intended to give PCSC and Freenome time to supplement the proxy statement/prospectus with information on recent events and to continue soliciting proxies. PCSC has also extended the deadline for Class A shareholders to submit redemption demands to 5:00 p.m. Eastern Time on July 13, 2026, while maintaining June 12, 2026 as the record date for voting.
Perceptive Capital Solutions Corp reported that its joint Registration Statement on Form S-4 with Freenome Holdings, Inc., related to their proposed business combination, was declared effective by the SEC on June 17, 2026. This clears a key regulatory step for taking Freenome public via PCSC’s SPAC structure.
The companies have scheduled an extraordinary general meeting of PCSC shareholders for July 9, 2026 to vote on the transaction, using a definitive proxy statement/prospectus mailed to shareholders of record as of June 12, 2026. If closing conditions are met, PCSC will be renamed Freenome, Inc. after the business combination.
Perceptive Capital Solutions Corp (PCSC) shareholders approved an amendment extending the deadline to complete an initial business combination from June 13, 2026 to June 13, 2027. This change was adopted at an extraordinary general meeting and the amendment was filed in the Cayman Islands on June 10, 2026.
Shareholder turnout represented about 76.5% of total voting power, with 8,515,798 votes for the extension, 75 against and 4,866 abstentions. Because support was sufficient, a potential adjournment proposal was not needed.
In connection with the vote, holders of 754,008 Class A Ordinary Shares redeemed their shares for approximately $10.82 per share, for total cash redemptions of about $8.16 million. After these redemptions, approximately $85.17 million remains in PCSC’s trust account for use in completing a future business combination, subject to remaining shareholders’ redemption rights.